EUVIMEDEUVIMED entdecken
Crossref

Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients

Irene Francés Alexandre, Ana Gea Peña, Ana Tobalina García, Juan José Domínguez-García, Elena Alejo Alonso, Ana Pilar González-Rodríguez, Irene Padilla, Maialen Sirvent Auzmendi, Ana Lobo Olmedo, Ana María Vale López, Irene Castaño Caballero, Evelyn Valencia und 13 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2025.08.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Irene Francés Alexandre und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain. Hauptthemen laut MEDLINE: Multiple Myeloma, Mucositis, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Autologous stem cell transplantation (ASCT) with melphalan 200 mg/m² remains a standard treatment for multiple myeloma (MM). We analyzed the incidence and risk factors associated with the development of mucositis in 1,268 MM patients who underwent ASCT between 2017 and 2022 across 13 national centers. RESULTS: Median age was 60 years (24-77), and 44% were female. Induction therapy included chemotherapy or cyclophosphamide (principally VCD) in 32%, and 21% had creatinine > 1 mg/dL. Melphalan was administered in a single day (Mel1) in 52% and over 2 days (Mel2) in 48%. Prophylaxis measures included cryotherapy (75%), G-CSF (78%) and antibiotics (37%). Mucositis occurred in 84% of patients, with 26% experiencing severe cases (WHO grade III-IV), which were significantly associated with increased intravenous opioids use, parenteral nutrition, and febrile episodes. Severe mucositis was more common in women (32% vs. 22%), patients over 60 (53% vs. 60%), chemotherapy induction (37% vs. 20%), creatinine > 1 mg/dL (34% vs. 24%), those not receiving G-CSF (35% vs. 24%) or antibiotic (36% vs. 16%). It was also more common with single day melphalan (29% vs. 24%). In the multivariable analysis, all factors except chemotherapy-based induction were identified as independent predictors of severe mucositis. CONCLUSION: In our population, an increased incidence of severe mucositis was observed in nonmodifiable factors such as sex and renal function. However, the implementation of modifiable factors, including the use of prophylactic G-CSF or antibiotics and administering melphalan over 2 days could diminish the severity of this complication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaMucositisHematopoietic Stem Cell TransplantationHumansFemaleMiddle AgedMaleTransplantation, AutologousAgedAdultRisk FactorsYoung AdultIncidenceMelphalan

Stichwörter der Autor:innen

Adverse effects of drugChemotherapyHematopoietic stem cell transplantationPlasma cell neoplasmSupportive care

Substanzen

Melphalan

Autor:innen und Institutionen

  • Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
  • Hospital Universitario de Salamanca/IBSAL/Cancer Research-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
  • Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
  • Complejo Asistencial Universitario de León, León, Castilla y León, Spain.
  • Hospital Universitario de Donostia, Gipuzkoa, País Vasco, Spain.
  • Hospital Universitario de Cruces, Barakaldo. Bizkaia, Spain.

Zitieren

APA

Francés Alexandre, I., Gea Peña, A., Tobalina García, A., Domínguez-García, J. J., Alejo Alonso, E., González-Rodríguez, A. P., Padilla, I., Sirvent Auzmendi, M., Lobo Olmedo, A., Vale López, A. M., Castaño Caballero, I., Valencia, E., Melero Valentín, P., Etxeguren Urkixo, I., Luque Romero, M. L. M., Larreina Pérez, J., Puertas Martínez, B., Escalante Barrigón, F., Oviedo Madrid, M., …, & Ocio, E. M. (2026). Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.018

Vancouver

Francés Alexandre I, Gea Peña A, Tobalina García A, Domínguez-García JJ, Alejo Alonso E, González-Rodríguez AP, et al. Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.08.018

BibTeX
@article{FrancsAlexandre2026,
  author = {Francés Alexandre, Irene and Gea Peña, Ana and Tobalina García, Ana and Domínguez-García, Juan José and Alejo Alonso, Elena and González-Rodríguez, Ana Pilar and Padilla, Irene and Sirvent Auzmendi, Maialen and Lobo Olmedo, Ana and Vale López, Ana María and Castaño Caballero, Irene and Valencia, Evelyn and Melero Valentín, Paula and Etxeguren Urkixo, Ianire and Luque Romero, María de Las Mercedes and Larreina Pérez, Javier and Puertas Martínez, Borja and Escalante Barrigón, Fernando and Oviedo Madrid, María and Bannatyne Undabeitia, Julia and Gorostidi Álvarez, Irene and Puente Pomposo, María and Montes Gaisán, Carmen and Bermúdez Rodríguez, María Aranzazu and Ocio, Enrique María},
  title = {Variables Associated With the Risk of Severe Mucositis During Autologous Transplantation in Multiple Myeloma Patients},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2025.08.018}
}
Kostenlos starten →